Intravesical administration of γδ T cells successfully prevents the growth of bladder cancer in the murine model

Cancer Immunology, Immunotherapy

Volumn 58, Issue 4, 2009, Pages 493-502

  Yuasa, Takeshi ^a   Sato, Kiyoshi ^b   Ashihara, Eishi ^b   Takeuchi, Miki ^b   Maita, Shinya ^a   Tsuchiya, Norihiko ^a   Habuchi, Tomonori ^a   Maekawa, Taira ^b   Kimura, Shinya ^b  

^a AKITA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KYOTO UNIVERSITY HOSPITAL   (Japan)

Author keywords

T; Bladder cancer; Intravesical administration; Major histocompatibility complex; Zoledronic acid

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; ZOLEDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; HLA ANTIGEN CLASS 1; IMIDAZOLE DERIVATIVE; IMMUNOLOGIC FACTOR; LYMPHOCYTE ANTIGEN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BAGG ALBINO MOUSE; BLADDER CANCER; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER PATIENT; CELL THERAPY; CLINICAL FEATURE; CONTROLLED STUDY; CYSTECTOMY; CYTOLYSIS; DISEASE FREE SURVIVAL; FEMALE; GAMMA DELTA T LYMPHOCYTE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; MOUSE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; T LYMPHOCYTE SUBPOPULATION; TRANSURETHRAL RESECTION; ADOPTIVE IMMUNOTHERAPY; AGED; ANIMAL; BIOSYNTHESIS; BLADDER TUMOR; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; INTRAVESICAL DRUG ADMINISTRATION; KAPLAN MEIER METHOD; METHODOLOGY; PATHOLOGY; T LYMPHOCYTE; WESTERN BLOTTING;

ADMINISTRATION, INTRAVESICAL; AGED; ANIMALS; BLOTTING, WESTERN; DIPHOSPHONATES; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMIDAZOLES; IMMUNOHISTOCHEMISTRY; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY, ADOPTIVE; KAPLAN-MEIERS ESTIMATE; MALE; MICE; MICE, INBRED BALB C; PROGNOSIS; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES; URINARY BLADDER NEOPLASMS;

EID: 59449106667     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-008-0571-9     Document Type: Article

References (27)

1. SJ Jones SC Campbell 2006
2. J Gee AL Sabichi HB Grossman 2002 Chemoprevention of superficial bladder cancer Crit Rev Oncol Hematol 43 277 286
3. HW Herr VP Laudone RA Badalament HF Oettgen PC Sogani BD Freedman MR Melamed WF Whitmore Jr 1988 Bacillus Calmette-Guerin therapy alters the progression of superficial bladder cancer J Clin Oncol 6 1450 1455
4. TL Ratliff JK Ritchey JJ Yuan GL Andriole WJ Catalona 1993 T-cell subsets required for intravesical BCG immunotherapy for bladder cancer J Urol 150 1018 1023
5. H Kitamura T Torigoe I Honma E Sato H Asanuma Y Hirohashi N Sato T Tsukamoto 2006 Effect of human leukocyte antigen class I expression of tumor cells on outcome of intravesical instillation of bacillus calmette-guerin immunotherapy for bladder cancer Clin Cancer Res 12 4641 4644
6. J Bubenik 2003 Tumour MHC class I downregulation and immunotherapy Oncol Rep 10 2005 2008
7. HJ Gober M Kistowska L Angman P Jeno L Mori G De Libero 2003 Human T cell receptor gammadelta cells recognize endogenous mevalonate metabolites in tumor cells J Exp Med 197 163 168
8. D Kabelitz D Wesch W He 2007 Perspectives of gammadelta T cells in tumor immunology Cancer Res 67 5 8
9. K Sato S Kimura H Segawa A Yokota S Matsumoto J Kuroda M Nogawa T Yuasa Y Kiyono H Wada T Maekawa 2005 Cytotoxic effects of γδ T cells expanded ex vivo by a third generation bisphosphonate for cancer immunotherapy Int J Cancer 116 94 99
10. E Viey C Laplace B Escudier 2005 Peripheral gammadelta T-lymphocytes as an innovative tool in immunotherapy for metastatic renal cell carcinoma Expert Rev Anticancer Ther 5 973 986
11. F Halary MA Peyrat E Champagne M Lopez-Botet A Moretta L Moretta H Vié JJ Fournié M Bonneville 1997 Control of self-reactive cytotoxic T lymphocytes expressing gamma delta T cell receptors by natural killer inhibitory receptors Eur J Immunol 27 2812 2821
12. AB Bakker JH Phillips CG Figdor LL Lanier 1998 Killer cell inhibitory receptors for MHC class I molecules regulate lysis of melanoma cells mediated by NK cells, gamma delta T cells, and antigen-specific CTL J Immunol 160 5239 5245
13. D Kabelitz D Wesch E Pitters M Zöller 2004 Characterization of tumor reactivity of human V gamma 9V delta 2 gamma delta T cells in vitro and in SCID mice in vivo J Immunol 173 6767 6776
14. F Lozupone D Pende VL Burgio C Castelli M Spada M Venditti F Luciani L Lugini C Federici C Ramoni L Rivoltini G Parmiani F Belardelli P Rivera S Marcenaro L Moretta S Fais 2004 Effect of human natural killer and gammadelta T cells on the growth of human autologous melanoma xenografts in SCID mice Cancer Res 64 378 385
15. Y Ichimura T Habuchi N Tsuchiya L Wang C Oyama K Sato H Nishiyama O Ogawa T Kato 2004 Increased risk of bladder cancer associated with a glutathione peroxidase 1 codon 198 variant J Urol 172 728 732
16. M Nogawa T Yuasa S Kimura M Tanaka J Kuroda K Sato A Yokota S Segawa Y Toda S Kageyama T Yoshiki Y Okada T Maekawa 2005 Intravesical administration of small interfering RNA targeting PLK-1 successfully prevents the growth of bladder cancer J Clin Invest 115 978 985
17. S Kimura C Ito N Jyoko H Segawa J Kuroda M Okada S Adachi T Nakahata T Yuasa VC Filho H Furukawa T Maekawa 2005 Inhibition of leukemic cell growth by a novel anti-cancer drug (GUT-70) from Calophyllim brasiliense that acts by induction of apoptosis Int J Cancer 113 158 165
18. M Nogawa T Yuasa S Kimura J Kuroda K Sato H Segawa A Yokota T Maekawa 2005 Monitoring luciferase-labeled cancer cell growth and metastasis in in vivo models Cancer Lett 217 243 253
19. H Kitamura T Torigoe I Honma H Asanuma E Nakazawa K Shimozawa Y Hirohashi E Sato N Sato T Tsukamoto 2006 Expression and antigenicity of surviving, an inhibitor of apoptosis family member, in bladder cancer: implications for specific immunotherapy Urology 67 955 959
20. P Sharma Y Shen S Wen S Yamada AA Jungbluth S Gnjatic DF Bajorin VE Reuter H Herr LJ Old E Sato 2007 CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma Proc Natl Acad Sci USA 104 3967 3972
21. S Kimura E Ashihara T Maekawa 2006 New tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia Curr Pharm Biotechnol 7 371 379
22. RJ Motzer TE Hutson P Tomczak MD Michaelson RM Bukowski O Rixe S Oudard S Negrier C Szczylik ST Kim I Chen PW Bycott CM Baum RA Figlin 2007 Sunitinib versus interferon alfa in metastatic renal-cell carcinoma N Engl J Med 356 115 124
23. Y Kato Y Tanaka F Miyagawa S Yamashita N Minato 2001 Targeting of tumor cells for human gammadelta T cells by nonpeptide antigens J Immunol 167 5092 5098
24. E van Beek E Pieterman L Cohen C Lowik S Papapoulos 1999 Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates Biochem Biophys Res Commun 264 108 111
25. R Uchida E Ashihara K Sato S Kimura J Kuroda M Takeuchi E Kawata K Taniguchi M Okamoto K Shimura Y Kiyono C Shimazaki M Taniwaki T Maekawa 2007 Gamma delta T cells kill myeloma cells by sensing mevalonate metabolites and ICAM-1 molecules on cell surface Biochem Biophys Res Commun 354 613 618
26. K Sato T Yuasa M Nogawa S Kimura H Segawa A Yokota T Maekawa 2006 A third generation bisphosphonate, minodronic acid (YM529), successfully prevented the growth of bladder cancer in vitro and in vivo Br J Cancer 95 1354 1361
27. H Kobayashi Y Tanaka J Yagi Y Osaka H Nakazawa T Uchiyama N Minato H Toma 2007 Safety profile and anti-tumor effects of adoptive immunotherapy using gamma-delta T cells against advanced renal cell carcinoma: a pilot study Cancer Immunol Immunother 56 469 476